← Leaderboards
Stephen Matthew Sykes
Massachusetts General Hospital
$4,607,203
Attributed
$4,823,181
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $923.7K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,823,181 · 5
By mechanism
R01$3,607,954 · 2
R00$641,116 · 1
R21$431,956 · 1
K99$142,155 · 1
Top collaborators
- Dietmar J Kappes2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jing-Ruey Joanna Yeh$6,608,932
- David T Scadden$62,181,067
- Tao Cheng$5,783,202
- Charles P Lin$25,566,556
- Eng H. Lo$32,456,318
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularIn VivoIn VitroChemotherapyLeukemiaResistanceTranscription FactorAffectMalignant NeoplasmsSurvival RateHematopoietic NeoplasmsRecurrent DiseaseGene ExpressionDisease ProgressionGenesCell PhysiologyAcute Myelocytic LeukemiaMediatingSamplingSignal TransductionCell Differentiation ProcessCellsCell DeathPathway Interactions
Grant awards (15)
Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid Leukemia$571,213
R01 · FY2025 · CA · contact PI
Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid Leukemia$535,370
R01 · FY2024 · CA · contact PI
Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid Leukemia$575,727
R01 · FY2023 · CA · contact PI
Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy Resistance$347,976
R01 · FY2023 · CA · contact PI
Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy Resistance$303,529
R01 · FY2022 · CA · contact PI
Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy Resistance$264,526
R01 · FY2021 · CA · contact PI
Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy Resistance$163,237
R01 · FY2021 · CA · contact PI
Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy Resistance$427,763
R01 · FY2020 · CA · contact PI
Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy Resistance$418,613
R01 · FY2019 · CA · contact PI
Role of ThPOK in HSC Maintenance and Leukemogenesis$199,013
R21 · FY2017 · CA
Role of ThPOK in HSC Maintenance and Leukemogenesis$232,943
R21 · FY2016 · CA
Foxo transcription factors are required for maintenance of acute myeloid leukemia$229,469
R00 · FY2014 · CA · contact PI
Foxo transcription factors are required for maintenance of acute myeloid leukemia$162,647
R00 · FY2013 · CA · contact PI
Foxo transcription factors are required for maintenance of acute myeloid leukemia$249,000
R00 · FY2012 · CA · contact PI
Foxo transcription factors are required for maintenance of acute myeloid leukemia$142,155
K99 · FY2012 · CA · contact PI